Why the study?
Poststroke depression is common and increases mortality, yet the use of mainstay SSRIs remains controversial due to safety concerns and limited efficacy.
What is the impact of poststroke depression on quality of life and what is the role of SSRIs in its treatment?
What is the impact of poststroke depression on quality of life and what is the role of SSRIs in its treatment?
Poststroke depression is a significant clinical dilemma that worsens outcomes, and current treatment with SSRIs remains controversial due to safety and efficacy concerns.
May warrant suicide screening in PSD; leaves open prospective validation of biomarkers and MRI predictors.
It is known that the majority of patients are prone to develop depression following a stroke. Several biological factors, including the disruption of the hypothalamic and adrenal axis and changes in cortisol and interleukin 6 (IL6), are said to have an essential role in its development. Magnetic resonance imaging (MRI) scans point toward white matter lesions and lacunar infarcts as the primary pathological culprit. People affected by poststroke depression (PSD) are more likely to commit suicide or develop another ischemic event after the initial episode, which can likely increase the mortality related to PSD and stroke. Selective serotonin reuptake inhibitors (SSRIs) are the mainstay of treatment for PSD. However, it has a poor safety profile and is not very productive, making the use of SSRIs controversial, and further studies are required to prove its benefits concerning PSD. This literature review discusses the importance of PSD, how it impacts the quality of life of people affected by stroke, and its treatment.
No takes yet. Share an insight, caveat, or question.
Jamil et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: